Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.04.2022 | Clinical study

Biological DMARDs increase risk of acute coronary syndrome

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

The risk of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (AR) is increased after initiation of biological disease-modifying antirheumatic drugs (bDMARDs), say authors of a study published in Annals of Rheumatic Diseases. …
Literatur
Zurück zum Zitat Delcoigne B, et al. Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries Annals of the Rheumatic Diseases : 22 Mar 2022. Available from: URL: http://doi.org/10.1136/annrheumdis-2021-221996 Delcoigne B, et al. Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries Annals of the Rheumatic Diseases : 22 Mar 2022. Available from: URL: http://​doi.​org/​10.​1136/​annrheumdis-2021-221996
Metadaten
Titel
Biological DMARDs increase risk of acute coronary syndrome
Publikationsdatum
01.04.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-13149-y

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Temozolomide

Case report

Azd-1222